 Immunotherapy
"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1983 | 0 | 1 | 1 | | 1985 | 1 | 2 | 3 | | 1986 | 1 | 0 | 1 | | 1988 | 0 | 1 | 1 | | 1989 | 2 | 2 | 4 | | 1990 | 1 | 1 | 2 | | 1991 | 4 | 0 | 4 | | 1992 | 1 | 1 | 2 | | 1994 | 0 | 1 | 1 | | 1995 | 1 | 1 | 2 | | 1996 | 1 | 0 | 1 | | 1998 | 0 | 3 | 3 | | 1999 | 2 | 1 | 3 | | 2000 | 3 | 2 | 5 | | 2001 | 2 | 5 | 7 | | 2002 | 2 | 3 | 5 | | 2003 | 2 | 5 | 7 | | 2004 | 5 | 8 | 13 | | 2005 | 3 | 2 | 5 | | 2006 | 5 | 2 | 7 | | 2007 | 4 | 1 | 5 | | 2008 | 7 | 7 | 14 | | 2009 | 3 | 2 | 5 | | 2010 | 7 | 5 | 12 | | 2011 | 5 | 5 | 10 | | 2012 | 8 | 7 | 15 | | 2013 | 8 | 11 | 19 | | 2014 | 6 | 8 | 14 | | 2015 | 11 | 15 | 26 | | 2016 | 22 | 2 | 24 | | 2017 | 25 | 4 | 29 | | 2018 | 28 | 14 | 42 | | 2019 | 32 | 20 | 52 | | 2020 | 23 | 24 | 47 | | 2021 | 23 | 19 | 42 | | 2022 | 1 | 18 | 19 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Howard FM, Pearson AT, Nanda R. Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2022 Aug; 195(1):1-15.
-
Lau D, Khare S, Stein MM, Jain P, Gao Y, BenTaieb A, Rand TA, Salahudeen AA, Khan AA. Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer. Nat Commun. 2022 07 13; 13(1):4053.
-
Korpics MC, Katipally RR, Partouche J, Cutright D, Pointer KB, Bestvina CM, Luke JJ, Pitroda SP, Dignam JJ, Chmura SJ, Juloori A. Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):645-654.
-
Zattarin E, Manglaviti S, Apollonio G, Beninato T, Mazzeo L, Massa G, Bottiglieri A, Galli E, De Toma A, Occhipinti M, Brambilla M, Ferrara R, Ganzinelli M, Proto C, Garassino MC, de Braud F, Lo Russo G, Prelaj A. Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. Future Oncol. 2022 Jul; 18(23):2593-2604.
-
Donington JS. Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer: Exciting New Horizon in Early-Stage Lung Cancer Care. Ann Surg Oncol. 2022 09; 29(9):5344-5346.
-
Ascierto PA, Warner AB, Blank C, Caracò C, Demaria S, Gershenwald JE, Khushalani NI, Long GV, Luke JJ, Mehnert JM, Robert C, Rutkowski P, Tawbi HA, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021. J Transl Med. 2022 05 10; 20(1):200.
-
Mansurov A, Hosseinchi P, Chang K, Lauterbach AL, Gray LT, Alpar AT, Budina E, Slezak AJ, Kang S, Cao S, Solanki A, Gomes S, Williford JM, Swartz MA, Mendoza JL, Ishihara J, Hubbell JA. Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker. Nat Biomed Eng. 2022 07; 6(7):819-829.
-
Schild SE, Wang X, Bestvina CM, Williams T, Masters G, Singh AK, Stinchcombe TE, Salama JK, Wolf S, Zemla T, Duma N, Chun SG, Amini A, Kozono D, Watt C. Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer. Clin Lung Cancer. 2022 07; 23(5):e317-e320.
-
Eggermont AMM, Hamid O, Long GV, Luke JJ. Optimal systemic therapy for high-risk resectable melanoma. Nat Rev Clin Oncol. 2022 07; 19(7):431-439.
-
DuBois SG, Macy ME, Henderson TO. High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-13.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|